Doubts over the veracity of Theranos' claims to revolutionise the diagnostics market were circulating long before the Washington Post launched its devastating critique of the venture capital darling, according to emails shown to the Wall Street Journal. A military official raised doubts over the legality of Theranos' practices in 2012, and launched a formal inquiry with the FDA in the US over the company's plans to distribute its test without FDA clearance.
Doubts over the veracity of Theranos' claims to revolutionise the diagnostics market were circulating long before the Wall Street Journal launched its devastating critique of the venture capital darling, according to emails shown to the Washington Post. A military official raised doubts over the legality of Theranos' practices in 2012, and launched a formal inquiry with the FDA in the US over the company's plans to distribute its test without FDA clearance.